Zhong Xin, Wei Meng, Ouyang Jun, Cao Weibo, Cheng Zewei, Huang Yadi, Liang Yize, Zhao Rudong, Yu Wenbin
Department of Gastrointestinal Surgery, General Surgery, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Front Surg. 2022 May 17;9:868877. doi: 10.3389/fsurg.2022.868877. eCollection 2022.
To compare the short- and long-term outcomes of totally laparoscopic gastrectomy (TLG) with laparoscopic-assisted gastrectomy (LAG) in gastric cancer (GC) patients and evaluate the efficacy and safety of TLG.
This retrospective study was based on GC patients who underwent laparoscopic radical gastrectomy in the Qilu Hospital from January 2017 to December 2020. The groups' variables were balanced by using the propensity score-based inverse probability of treatment weighting (PS-IPTW). The primary outcomes were 3-year relapse-free survival (RFS) and 3-year overall survival (OS). Postoperative recovery and complications were the secondary outcomes.
A total of 250 GC patients were included in the study. There were no significant differences in baseline and pathological features between the TLG and the LAG groups after the PS-IPTW. TLG took around 30 min longer than LAG, while there were more lymph nodes obtained and less blood loss throughout the procedure. TLG patients had less wound discomfort than LAG patients in terms of short-term prognosis. There were no significant differences between groups in the 3-year RFS rate [LAG vs. TLG: 78.86% vs. 78.00%; hazard ratio (HR) = 1.14, 95% confidence interval (CI), 0.55-2.35; = 0.721] and the 3-year OS rate (LAG vs. TLG: 78.17% vs. 81.48%; HR = 0.98, 95% CI, 0.42-2.27; = 0.955). The lymph node staging was found to be an independent risk factor for tumor recurrence and mortality in GC patients with laparoscopic surgery. The subgroup analysis revealed similar results of longer operation time, less blood loss, and wound discomfort in totally laparoscopic distal gastrectomy, while the totally laparoscopic total gastrectomy showed benefit only in terms of blood loss.
TLG is effective and safe in terms of short- and long-term outcomes, with well-obtained lymph nodes, decreased intraoperative blood loss, and postoperative wound discomfort, which may be utilized as an alternative to LAG.
比较完全腹腔镜胃癌根治术(TLG)与腹腔镜辅助胃癌根治术(LAG)治疗胃癌(GC)患者的短期和长期疗效,并评估TLG的有效性和安全性。
本回顾性研究基于2017年1月至2020年12月在齐鲁医院接受腹腔镜根治性胃癌切除术的GC患者。采用基于倾向评分的逆概率处理加权法(PS-IPTW)平衡两组变量。主要结局指标为3年无复发生存率(RFS)和3年总生存率(OS)。术后恢复情况和并发症为次要结局指标。
本研究共纳入250例GC患者。PS-IPTW后,TLG组和LAG组的基线和病理特征无显著差异。TLG手术时间比LAG长约30分钟,但术中获取的淋巴结更多,术中失血更少。就短期预后而言,TLG患者的伤口不适比LAG患者少。两组的3年RFS率[LAG组 vs. TLG组:78.86% vs. 78.00%;风险比(HR)=1.14,95%置信区间(CI),0.55-2.35;P=0.721]和3年OS率(LAG组 vs. TLG组:78.17% vs. 81.48%;HR=0.98,95%CI,0.42-2.27;P=0.955)无显著差异。淋巴结分期是腹腔镜手术GC患者肿瘤复发和死亡的独立危险因素。亚组分析显示,完全腹腔镜远端胃癌根治术的手术时间更长、失血更少、伤口不适情况类似,而完全腹腔镜全胃切除术仅在失血方面有优势。
TLG在短期和长期疗效方面有效且安全,术中能良好获取淋巴结,减少术中失血和术后伤口不适,可作为LAG的替代术式。